Categories 2022 Press Releases Farmacosmo, First Quarter Results Revenues + 20% YoY at € 17.7 Million Post author By Antonio Buono Post date 22 April 2022 Farmacosmo, First Quarter Results Revenues + 20% YoY at € 17.7 Million
Categories 2022 Press Releases Risultati del Primo Trimestre ricavi + 20% YoY a € 17,7 mln crescono tutti i KPI sul portale Post author By Antonio Buono Post date 22 April 2022 Risultati del Primo Trimestre ricavi + 20% YoY a € 17,7 mln crescono tutti i KPI sul portale
Categories 2022 Press Releases Comunicazione Intermedia Periodo Di Stabilizzazione Post author By Mad Post date 11 April 2022 Comunicazione Intermedia Periodo Di Stabilizzazione
Categories 2022 Press Releases Interim Communication Period of Stabilization Post author By Antonio Buono Post date 11 April 2022 Interim Communication Period of Stabilization
Categories 2022 Press Releases Errata Corrige – Tempistiche di Pagamento del Dividendo Post author By Mad Post date 4 April 2022 Errata Corrige – Tempistiche di Pagamento del Dividendo
Categories 2022 Press Releases Errata Corrige – Dividend Payment Times Post author By Antonio Buono Post date 4 April 2022 Errata Corrige – Dividend Payment Times
Categories 2022 Press Releases Non categorizzato Comunicazione Intermedia Periodo Di Stabilizzazione Post author By Mad Post date 1 April 2022 Comunicazione Intermedia Periodo Di Stabilizzazione
Categories 2022 Press Releases Il CDA Approva i Dati Economico-Finanziari Al 31 Dicembre 2021 Post author By Mad Post date 1 April 2022 Il CDA Approva i Dati Economico-Finanziari Al 31 Dicembre 2021
Categories 2022 Press Releases Interim Communication Period of Stabilization Post author By Antonio Buono Post date 1 April 2022 Interim Communication Period of Stabilization
Categories 2022 Press Releases The Board of Directors approves the economic and financial data as at 31 december 2021 Post author By Antonio Buono Post date 1 April 2022 The Board of Directors approves the economic and financial data as at 31 december 2021
Farmacosmo InvestorsFarmacosmo Investors